Market cap
$40,243 Mln
Revenue (TTM)
$17,348 Mln
P/E Ratio
25.8
P/B Ratio
4.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.2 %
-
ROCE
-- %
-
Industry P/E
33.27
-
EV/EBITDA
16.2
-
Debt to Equity
1.7
-
Book Value
$--
-
EPS
$1.3
-
Face value
--
-
Shares outstanding
1,164,426,972
10 Years Aggregate
CFO
$27,357.00 Mln
EBITDA
$39,495.00 Mln
Net Profit
$-20,927.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Teva Pharma Industries Ltd ADR (TEVA)
| 4.7 | -4.7 | 10.9 | 86.7 | 63.0 | 25.3 | -4.6 |
|
BSE Sensex
| -8.9 | 2.5 | 2.2 | -5.7 | 6.8 | 8.0 | 11.3 |
|
S&P Midcap 400
| 14.3 | 6.0 | 14.5 | 27.2 | 13.9 | 7.0 | 10.0 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Teva Pharma Industries Ltd ADR (TEVA)
| 41.6 | 109.8 | 14.5 | 13.9 | -17.0 | -1.5 | -36.4 |
|
S&P Midcap 400
| 5.9 | 12.1 | 14.4 | -14.5 | 23.2 | 11.8 | 24.1 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Teva Pharma Industries Ltd ADR (TEVA)
|
32.7 | 40,242.6 | 17,348.0 | 1,564.0 | 13.1 | 20.2 | 25.8 | 4.9 |
| 222.2 | 397,122.0 | 62,819.0 | 3,639.0 | 14.1 | -- | 109.6 | 50.5 | |
| 348.0 | 191,704.4 | 37,238.0 | 7,800.0 | 31.7 | 82.9 | 24.7 | 20.9 | |
| 1,118.2 | 1,035,267.1 | 72,249.5 | 25,275.0 | 44.1 | 91.9 | 41.3 | 32.5 | |
| 127.2 | 155,928.8 | 29,734.0 | 9,216.0 | 39.5 | 40.9 | 17.1 | 6.6 | |
| 233.8 | 579,826.4 | 96,362.0 | 21,040.0 | 20.2 | 26.2 | 27.9 | 7.1 | |
| 115.6 | 298,256.0 | 65,593.0 | 8,935.0 | 24.7 | 18.3 | 34 | 6.4 | |
| 152.5 | 293,693.5 | 56,053.0 | 13,533.8 | 30.3 | 32.7 | 22.1 | 7.6 | |
| 26.2 | 149,154.5 | 63,315.0 | 7,491.0 | 16.7 | 8.1 | 20 | 1.6 | |
| 15.5 | 50,144.0 | 4,777,450.3 | 203,326.8 | 13.7 | 2.8 | 42.9 | 1.0 |
Shareholding Pattern
View DetailsAbout Teva Pharma Industries Ltd ADR (TEVA)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various... dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel. Read more
-
Executive VP & CFO
Mr. Eliyahu Sharon Kalif
-
President, CEO & Director
Mr. Richard D. Francis
-
Headquarters
Tel Aviv-Yafo
-
Website
FAQs for Teva Pharma Industries Ltd ADR (TEVA)
What is the current share price of Teva Pharma Industries Ltd ADR (TEVA) Today?
The share price of Teva Pharma Industries Ltd ADR (TEVA) is $32.67 (NYSE) as of 17-Jun-2026 11:47 EDT. Teva Pharma Industries Ltd ADR (TEVA) has given a return of 63.02% in the last 3 years.
What is the current PB & PE ratio of Teva Pharma Industries Ltd ADR (TEVA)?
The P/E ratio of Teva Pharma Industries Ltd ADR (TEVA) is 25.79 times as on 12-Jun-2026, a 22 discount to its peers’ median range of 33.27 times.
The P/B ratio of Teva Pharma Industries Ltd ADR (TEVA) is 4.89 times as on 12-Jun-2026, a 16 discount to its peers’ median range of 5.79 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
25.96
|
4.63
|
|
2024
|
-15.24
|
4.65
|
|
2023
|
-21.23
|
1.58
|
|
2022
|
-4.14
|
1.30
|
|
2021
|
21.19
|
0.86
|
What is the 52 Week High and Low of Teva Pharma Industries Ltd ADR (TEVA)?
The 52-week high and low of Teva Pharma Industries Ltd ADR (TEVA) are Rs 37.34 and Rs 14.99 as of 17-Jun-2026.
What is the market cap of Teva Pharma Industries Ltd ADR (TEVA)?
Teva Pharma Industries Ltd ADR (TEVA) has a market capitalisation of $ 40,243 Mln as on 12-Jun-2026. As per SEBI classification, it is a Mid Cap company.
Should I invest in Teva Pharma Industries Ltd ADR (TEVA)?
Before investing in Teva Pharma Industries Ltd ADR (TEVA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.